跳至主要内容
临床试验/NCT02056522
NCT02056522已完成不适用

Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging: the MDS (Melanoma Detecting System)

Orlucent, Inc2 个研究点 分布在 1 个国家目标入组 357 人开始时间: 2016年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Orlucent, Inc
入组人数
357
试验地点
2
主要终点
To validate the performance of MDS

研究概览

简要总结

The use of MDS to access the presence of melanoma in the skin.

详细描述

A topical agent is applied to suspicious skin lesions and imaged. The images are analyzed to provide a score that correlates with the probability for the presence of melanoma in the lesion.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
21 Years 至 97 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Individuals with skin lesion with one or more of the ABCDE features and recommended for a skin biopsy.
  • The lesion is accessible to the imaging device, with at least 1 cm of skin around the lesion that is accessible to the MDS.
  • Male and female ≥ 21 years old.
  • Subject is capable of giving written informed consent.
  • Primary excision.

排除标准

  • The lesion is less than 1 cm from the eyes.
  • The lesion is on the palms of hands or soles of the feet.
  • Mucosal lesion.
  • Pregnant females.
  • Low study procedure compliance.
  • Patients who are mentally or physically unable to comply with all aspects of the study.
  • Undergoing chemotherapy.
  • Minor or legally incompetent and not able to sign the consent form.
  • Patient previously tested by MDS and was diagnosed with melanoma during the study.

结局指标

主要结局

To validate the performance of MDS

时间窗: 28 days

次要结局

  • To calculate and specify the PPV and NPV of the MDS for melanoma detection when used as an adjacent tool to visual skin examination.(28 days)

研究者

发起方
Orlucent, Inc
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Non-invasive Melanoma Assessment Using a Topical... | 临床试验